Nestle's scientific skew curbs its appetite for weak food brands
date:Jun 05, 2014
last month, buying the rights to several injectable wrinkle treatments for $1.4 billion.

It recently sold its PowerBar business and the bulk of its Jenny Craig diet business and said there could be more divestitures of brands whose sales growth, profit margins and rate of return on invested capital pull down that of the whole group.

We are living in a riskier place and going riskier places strategically, like Nestle Health Sciences. That equals more margin, Bulcke said. To get higher margins,
3/5 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/03 12:38